Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia = Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia

다국어 초록 (Multilingual Abstract)

Background/Aims: Adherence to tyrosine kinase inhibitors (TKIs) has become a critical aspect of care in chronic myeloid leukemia (CML). We aimed to examine the association of TKI adherence with overall survival (OS) outcomes in Korean patients diagnosed with CML and treated with TKIs using data from the National Health Information Database.
Methods: This study included 2,870 CML patients diagnosed between 2005 and 2013. Drug adherence was evaluated according to the medication possession ratio (MPR) and classified as high adherence (i.e., MPR ≥ 0.95 [upper 50%]), moderate adherence (i.e., MPR ≥ 0.68 and < 0.95 [middle 25%]), and low adherence (i.e., MPR < 0.68 [lower 25%]).
Results: The median MPR was 0.95 (range, 0 to 4.67). Male sex (p = 0.003), age < 70 years (p < 0.001), high income (≥ 30%, p < 0.001), and maintaining frontline TKI (< 0.001) were associated with better adherence. Adherence to dasatinib was the lowest (vs. imatinib or nilotinib, p < 0.001). Compared with high MPR patients, those with moderate MPR (hazard ratio [HR], 4.90; 95% confidence interval [CI], 3.87 to 6.19; p < 0.001) and low MPR (HR, 11.6; 95% CI, 9.35 to 14.42; p < 0.001) had poorer OS.
Conclusions: Adherence to TKI treatment is an important factor predicting survival outcomes in Korean CML patients. Male sex, age < 70 years, high income, and maintaining frontline TKI are associated with high adherence to TKI. Thus, those without these characteristics should be closely monitored for treatment adherence.

참고문헌 (Reference)

1 Carlesso N, "Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription(STAT)proteins in hematopoietic cell lines transformed by Bcr/Abl" 183 : 811-820, 1996

2 Darkow T, "Treatment interruptions and non-adherence with imatinib and associated healthcare costs : a retrospective analysis among managed care patients with chronic myelogenous leukaemia" 25 : 481-496, 2007

3 Larfors G, "The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia" 98 : 398-406, 2017

4 Halpern R, "The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations : a retrospective claims analysis of female health plan enrollees with osteoporosis" 17 : 25-39, 2011

5 National Health Insurance Service, "The Effect of National Health Examination Program on the Early Diagnosis of Diseases, Medical Utilization, and Health Outcome" National Health Insurance Service 2011

6 Wu EQ, "Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia" 26 : 2861-2869, 2010

7 Ector GICG, "Primary therapy and relative survival among elderly patients with chronic myeloid leukemia : a population-based study in the Netherlands, 1989-2017" 34 : 3408-3412, 2020

8 Noens L, "Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia : the ADAGIO study" 113 : 5401-5411, 2009

9 Ganesan P, "Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia" 86 : 471-474, 2011

10 Kim YI, "National Health Insurance System of Korea" National Health Insurance Service 2015

11 Noens L, "Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia : current situation and future challenges" 99 : 437-447, 2014

12 Hochhaus A, "Long-term outcomes of imatinib treatment for chronic myeloid leukemia" 376 : 917-927, 2017

13 Fritz A, "International Classification of Diseases for Oncology" World Health Organization 2000

14 National Health Insurance Service (KR), "History of the NHIS" National Health Insurance Service

15 Wu EQ, "Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients" 26 : 61-69, 2010

16 Cortes JE, "Final 5-year study results of DASISION : the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial" 34 : 2333-2340, 2016

17 Hochhaus A, "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia" 34 : 966-984, 2020

18 Huang X, "Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy" 118 : 3123-3127, 2012

19 Sawyers CL, "Dominant negative MYC blocks transformation by ABL oncogenes" 70 : 901-910, 1992

20 Kiguchi T, "Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase" 33 : 506-508, 2009

21 Hehlmann R, "Chronic myeloid leukemia in 2020" 4 : e468-, 2020

22 Goldberg SL, "Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib" 29 : 1075-1082, 2013

23 de Almeida MH, "Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia : a Brazilian single-center cohort" 130 : 16-22, 2013

24 Yood MU, "Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia" 28 : 213-219, 2012

25 Osterberg L, "Adherence to medication" 353 : 487-497, 2005

26 Jabbour E, "Adherence to BCR-ABL inhibitors : issues for CML therapy" 12 : 223-229, 2012

27 Marin D, "Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib" 28 : 2381-2388, 2010

28 Peterson AM, "A checklist for medication compliance and persistence studies using retrospective databases" 10 : 3-12, 2007